KR20130024316A - Cosmetic composition for improving skin condition comprising growth factor and cytokine induced human placenta - Google Patents
Cosmetic composition for improving skin condition comprising growth factor and cytokine induced human placenta Download PDFInfo
- Publication number
- KR20130024316A KR20130024316A KR1020110087685A KR20110087685A KR20130024316A KR 20130024316 A KR20130024316 A KR 20130024316A KR 1020110087685 A KR1020110087685 A KR 1020110087685A KR 20110087685 A KR20110087685 A KR 20110087685A KR 20130024316 A KR20130024316 A KR 20130024316A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- cosmetic composition
- weight
- parts
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Abstract
Fibroblast growth factor-2 (FGF-2), Lantis (CCL5), Interleukin-10 (IL-10), Epithelial cell growth factor (EGF), Transformation growth factor-β1 (TGFβ1), Tumor necrosis It relates to a cosmetic composition for improving skin condition comprising a similar placental composition consisting of factor-α (TNF-α), interleukin-8 (IL-8), and interferon-γ (IFN-γ) as an active ingredient.
The cosmetic composition according to the present invention is effective in improving wrinkles, regenerating, improving skin elasticity, antioxidant, preventing skin aging, improving stretch marks, slimming, wound healing, reducing scars, improving mushrooms, improving whitening or moisturizing.
Description
The present invention relates to a cosmetic composition for skin improvement comprising a placental derived growth factor and a similar placental composition containing cytokines.
Skin is the largest organ of the human body and occupies about 16% of the total body volume. It is a very important organ that plays various roles such as protective function, barrier function, temperature control function, excretory function and respiratory function. However, with age, various external factors such as various pollutants, strong ultraviolet rays, stress and nutritional deficiency, skin cells are damaged, cell proliferation is not properly performed, the skin's constituent epidermis, As the thickness of dermis and subcutaneous tissue becomes thin and lipid composition and content of Lipid barrier, which is in charge of skin barrier, changes, its function is drastically lowered, so the moisture content of skin is lowered. Due to this, wrinkles, loss of elasticity and keratinization occur on the skin.
As human skin ages, the secretion of various hormones that regulate metabolism decreases, and the function and activity of immune cells and skin cells decreases, thus reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms. This results in decreased elasticity of the skin, rough skin, and endogenous aging (Arch Dermatol., 130: 87-95 (1994)), in which deep wrinkles and pigments are deposited. In addition, it is known that exogenous aging that results in wrinkles, decreased elasticity, and increased skin dryness due to photoaging by various pollutants and ultraviolet rays, as well as the appearance of spots, freckles, and mushrooms (J. Am.Acad.Drmatol., 21: 610-613 (1989).
Various studies have been conducted to investigate the mechanism of aging of the skin, revealing various causes of skin aging. The skin is the outermost tissue covering the human body and is in contact with various harmful environments. When the skin is dried by changes in temperature, humidity or wind, the skin's physiological activity as a protective barrier against the outside is reduced, thereby promoting aging. In particular, they are always in contact with oxygen and continue to suffer from photooxidative damage induced by reactive oxygen species by exposure to ultraviolet light. Ultraviolet radiation causes free radicals in the skin, which in turn increases the damage and pigmentation of skin cells, leading to a loss of direct function of the skin's major components and leading to skin aging. Free radicals are a cause of disease and aging in the human body and can be evaluated as a measure of antioxidant activity and anti-aging activity of free radicals. The characteristics of skin aging include decreased elasticity, wrinkles, blemishes or freckles, and one of the causes may be chain breakage of collagen and elastin, which are elastic fibers caused by lipid peroxidation, abnormal crosslinking and It is a chain break of hyaluronic acid. Lipid peroxidation is caused by oxidative stress, and in the process, ROS, free radicals, superoxides, hydroxyl radicals and nitric oxides are produced. The production of these free radicals has been reported not only to be a preliminary step in metabolic activation that is harmful to skin, but also to cause skin cell and tissue damage. In particular, expression of matrix metalloproteinases (MMPs) may be induced by reactive oxygen species in relation to wrinkles to cause wrinkles by denaturing or destroying collagen or elastin, which gives elasticity to the skin. Since collagen (or elastin) is the most abundant component of the matrix of the dermal layer of the skin, the control of biosynthesis and degradation of collagen is a key part of the skin aging process.
Retinoic acid, epidermal growth factor (EGF), TGF (trans forming growth factor), carcinogenic factor; Cardinale G. et al., Adv.Enzymol., 41, p 425, 1974), animal placental proteins (JP8-231370), betulinic acid (betulinic acid (JP8-208424)) and chlorella extracts (JP9-40523, JP10-36283, fibroblast proliferation). .
If the skin's moisturizing function is not functioning, it can cause skin elasticity. That is, loss of moisture of the skin is an important factor of skin aging. The moisture balance of the skin is controlled by the epidermis. The stratum corneum of the epidermis is an accumulation of dead cells, but plays a very important role in maintaining the moisture of the skin. The human body is composed mostly of water, which plays an important role in the maintenance of life. Moisture in normal skin is 70% in the body and 20% in the stratum corneum to support the elasticity and flexibility of the skin. When the water content of the stratum corneum is 10% or less, it is known that the skin becomes dry and causes skin troubles. The amount of moisture in the stratum corneum produced by regular keratinization is always 10-20%. Currently, the method of retaining moisture in the skin uses an occlusive agent, which is a hydrophobic substance that promotes water retention by forming a barrier on the skin that prevents water loss. The most commonly used occlusion agents include petrolatum, lanolin, cocoa butter, mineral oil and silicone.
Melanin absorbs the light energy of sunlight UV and protects the skin from UV damage.It also protects the skin from external harmful factors such as trapping harmful oxygen and free radicals generated in the skin. . However, overproduction of melanin not only damages the skin, but also causes pigmentation of the skin to form spots, freckles, and even cause skin cancer. In addition, the food is known to cause browning phenomenon, the development of drugs for the purpose of preventing melanin overproduction in recent years has been actively developed. Currently, the development of a whitening agent for skin beauty is known to reduce the color of the melanin produced by the pigmentation and to inhibit the activity of tyrosinase, an enzyme that forms melanin pigment. The best known inhibitors of tyrosinase, an important enzyme in melanin synthesis, include chelators such as Kojiic acid and substrate-like substances such as arbutin. In addition, plant extracts include lettuce extract, licorice extract and the like. However, these whitening raw materials have the disadvantage that the effect does not last long because of low stability, so the application range of the product is very narrow.
Placenta, on the other hand, is an organ that develops in the womb of a pregnant mammal. Placenta contains essential amino acids, melatonin, RNA, DNA and other nucleic acid components, antioxidant enzymes, hyaluronic acid, antioxidants, immune cofactors (cytocine), placental peptides, insulin-like-grouth factor Growth factors such as epidermal growth factors (EGFS) and cytokines are known to be useful for fatigue recovery and immune enhancement.
Various methods of manufacturing cosmetics using such placental extracts have been disclosed, but these methods are directly extracted from mammalian placenta including humans and extracted and used as cosmetic raw materials, according to the extraction method and raw materials, It is difficult to control the content, there is a risk of causing an immune rejection reaction in the case of skin, especially skin wounds, and since it is extracted from nature, there is a restriction of supply and demand of raw materials. In the case of placenta, the sale of cosmetics containing placenta extract is prohibited by law for ethical issues. Therefore, there is an urgent need for the development of active ingredients that are safe for the living body, have no ethical problems, have a stable active ingredient, and have excellent effects on improving skin, such as wrinkle improvement, regeneration, skin elasticity improvement, antioxidants, and anti-aging of the skin. .
In the present invention, various skin conditions such as wrinkle improvement, regeneration, skin elasticity improvement, antioxidant, skin anti-aging, stretch marks, slimming, wound healing (Wound Healing), scar relaxation, mushroom improvement, whitening, moisturizing improvement, hair growth or itching improvement It is possible to provide a cosmetic composition effective for.
Fibroblast growth factor-2 (FGF-2), Lantis (CCL5), Interleukin-10 (IL-10), Epithelial cell growth factor (EGF), Transformation growth factor-β1 (TGFβ1), Tumor necrosis It relates to a cosmetic composition for improving skin condition comprising a similar placental composition consisting of factor-α (TNF-α), interleukin-8 (IL-8), and interferon-γ (IFN-γ) as an active ingredient.
Hereinafter, the cosmetic composition for improving skin conditions according to the present invention will be described in more detail.
In the present invention, after analyzing the growth factor and cytokines derived from the placenta as a raw material of the cosmetic composition, a similar placental composition using the recombinant them is used.
In the present invention, the similar placental composition is fibroblast growth factor-2 (Basic fibroblast growth factor, FGF-2), Lantis (RANTES, CCL5), Interleukin-10 (IL-10), epithelial cell growth factor (Epidermal growth factor, EGF), transformation growth factor-β1 (TGFβ1), tumor necrosis factor-α (TNF-α), interleukin-8 (Interleukin-8, IL -8) and interferon-γ (Interferon-γ, IFN-γ) as an active ingredient.
The content of the components constituting the pseudo placental composition is not particularly limited, and, for example, based on 100 parts by weight of the similar placental composition, fibroblast growth factor-2 (FGF-2) 0.0000001 to 0.00001 parts by weight, Lantis (CCL5) 0.000001 to 0.0001 parts by weight, interleukin-10 (IL-10) 0.00000001 to 0.000001 parts by weight, epithelial cell growth factor (EGF) 0.00001 to 0.001 parts by weight, transforming growth factor-β1 (TGFβ1) 0.0000001 to 0.00001 parts by weight, tumor necrosis 0.00000001 to 0.000001 parts by weight of factor-α (TNF-α), 0.000001 to 0.0001 parts by weight of interleukin-8 (IL-8) and 0.00000001 to 0.000001 parts by weight of interferon-γ (IFN-γ) may be used. Within this range, the effect of improving the skin condition of the similar placental composition is excellent.
In addition, in the present invention, the similar placental composition is activin, adiponectin, Ang, BMP, CSF, Flt-3 ligand, follistatin, fractalkin, GRO, HGF, hGH, I-309, IGF, IL-13, IL-15 , IL-17, IL-1α IL-1β, IL-2, IL-3, IL-4, IL-6, IP-10, Raptin, MCP, MIP, PDGF-AA, PDGF-BB, Lecistin, sCD40L It may further comprise one or more selected from the group consisting of, SCF, SDF, TIMP and VEGF.
In the present invention, when the similar placental composition is applied to a cosmetic composition, wrinkle improvement, regeneration, skin elasticity improvement, antioxidant, skin anti-aging, stretch marks, slimming, wound healing (Wound Healing), scar relaxation, mushroom improvement, whitening improvement or moisturizing The skin improvement effect, such as improvement, can be acquired.
The active ingredient used in the present invention, that is, the placental-derived growth factor and cytokine, can be used those isolated or extracted from human-derived materials or cultures, chemically synthesized or DNA recombinant methods.
In the present invention, the second processed through liposomes, novasome or microfluidics, etc. may be used to improve efficiency for skin penetration and improve stability in cosmetic compositions with a similar placental composition.
In the present invention, for example, liposomes containing analogous placental compositions can be prepared using phospholipids or phospholipid derivatives, polyols, surfactants, fatty acids, oils, thickeners, solvents and the like. Here, liposomes are spherical vesicles in which amphiphilic polymer materials including phospholipids associate themselves to form a lipid bilayer.
In the present invention, the phospholipids or derivatives thereof include, for example, phosphatidylcholine, phosphatidylglycerol, dimyristoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, dioleoyl phosphatidylcholine, dioleoyl phosphadiyl glycerol, and disteroyl phosphatidyl ethanolamine. One or more selected from the group consisting of -N-poly (ethylene glycol) (DSPE-PEG), lecithin, hydrogenated lecithin, and the like, and as an oil which serves as a dissolving agent or dissolving aid of a similar placental composition, From vegetable oils such as liquid paraffin, soybean oil, corn oil, castor oil, cottonseed oil, canola oil, sunflower seed oil, safflower oil, sesame oil and peanut oil, tocopherol oil, ethyl oleate, caprylic / caprylic acid triglyceride, and the like. One or more selected may be used and, for example, as a polyol, One or more selected from the group consisting of ethylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isoprene glycol, pentylene glycol, erythritol, ziitol, sorbitol and the like can be used. Moreover, as surfactant, anionic surfactant (alkylacyl glutamate, alkyl phosphate, alkyl lactylate, dialkyl phosphate, trialkyl phosphate etc.), cationic surfactant, amphoteric surfactant, and nonionic surfactant (alkoxy, for example) Or at least one selected from the group consisting of a linked alkyl ether, an alkoxylated alkyl ester, an alkyl polyglycoside, a polyglyceryl ester, a sugar ester, and the like).
Liposomes containing pseudo-placental compositions can be prepared by dissolving phospholipids, oils, surfactants and polyols with appropriate amounts of solvents by appropriate methods such as heating, using homogenizers or mixing using high pressure homogenizers. . The liposomes may further include various substances such as thickeners for the purpose of improving stability.
The similar placental composition according to the present invention or a composition comprising liposomes containing the similar placental composition may be prepared with cosmetic compositions well known in the art.
The similar placental composition or the composition including the liposomes containing the similar placental composition may be included in an amount of 0.000001 to 10 parts by weight based on the total weight of the cosmetic composition.
In the present invention, the cosmetic composition may further include components commonly used in cosmetic compositions. Components further included in the cosmetic composition include, for example, fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, and surfactants. Selected from the group consisting of water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents and lipid vesicles You can use more than one.
In addition, the cosmetic composition in the present invention may be prepared in any formulation commonly prepared in the art, for example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, Massage Cream, Nourishing Cream, Moisture Cream, Hand Cream, Essence, Nourishing Essence, Pack, Soap, Shampoo, Cleansing Foam, Cleansing Lotion, Cleansing Cream, Body Lotion, Body Cleanser, Latex, Press Powder, Loose Powder and Eye Shadow It may be formulated with one or more selected from the group.
Cosmetic composition according to the invention contains growth factors and cytokines derived from placenta, more specifically fibroblast growth factor-2 (FGF-2), Lantis (CCL5), interleukin-10 (IL-10) , Epidermal growth factor (EGF), transforming growth factor-β1 (TGFβ1), tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8) and interferon-γ (IFN-γ) .
The cosmetic composition has various skin conditions such as wrinkle improvement, regeneration, skin elasticity improvement, antioxidant, skin anti-aging, stretch marks, slimming, wound healing (Wound Healing), scar relief, blotch improvement, whitening, moisturizing, hair growth and itching improvement It is effective in improving skin, especially in wrinkles, elasticity, moisturizing and whitening. In addition, the cosmetic composition is a safe composition.
Hereinafter, preferred embodiments and experimental examples are provided to facilitate understanding of the present invention. However, the following examples and experimental examples are provided only to more easily understand the understanding of the present invention, and the contents of the present invention are not limited by the examples.
Manufacturing example 1: similar Placenta Preparation of the composition
Similar placental compositions were prepared as shown in Table 1 below.
Manufacturing example One: Example And Comparative example
Examples and comparative examples were prepared to conduct clinical trials on the skin wrinkle effect, elasticity improvement effect and skin improvement effect of the cosmetic composition containing the similar placental composition of the present invention.
Experimental Example 1: skin wrinkle improvement
The skin wrinkle improvement effect of the cosmetic composition containing the analogous placental composition according to the present invention was evaluated in 20 healthy women aged 30 to 45 years. First, 20 women were divided into two groups (A and B), and the cosmetic composition according to the example was applied to the group A, and the cosmetic composition according to the comparative example was applied to the facial group twice a day (morning and evening) for 3 months. . After 3 months, the degree of wrinkle improvement was evaluated by subject's questionnaire and image analysis of wrinkles.
The subject's questionnaire was judged as four stages of no improvement, slight improvement, moderate improvement and significant improvement compared to before use, and the results are shown in Table 3 below.
In addition, image analysis of wrinkles is performed by taking a replica under the eye before the experiment is started, and replicas immediately after the experiment is completed at the same area under the eye. The density was measured. The measurement results of wrinkle density by image analysis are shown in Table 4 below as a reduction ratio for wrinkle density before use.
As shown in the results of Tables 3 and 4, it can be seen that the skin wrinkle improvement effect of the embodiment containing the similar placental composition is very excellent.
Experimental Example 2: skin elasticity effect
The skin elasticity enhancing effect of the cosmetic composition containing the similar placental composition of the present invention was measured. 20 healthy women (average age 36 years old) of 20 years or older (average age 36 years) are divided into two groups (A and B) at a temperature of 24 to 26 ° C and a humidity of 75%. In the cosmetic composition according to the comparative example was applied twice a day (morning and evening) for 12 weeks, mainly around the eyes, skin elasticity was measured using a skin elasticity measuring instrument (Cutometer MPA580, Conrage + Khazaka, Germany). The test results were described as R2 (R2 (12 weeks) -R2 (0 weeks)) values of the cutometer MPA580, where R2 values indicate the properties of gross elasticity, and the results are shown in Table 5 below.
As shown in the results of Table 5, the skin elasticity of the embodiment containing the similar placental composition was more than three times better than the comparative example, it was confirmed that the elasticity enhancement effect of the above example is excellent.
Experimental Example 3: skin color improvement effect
The skin color improvement effect of the cosmetic composition containing the similar placental composition of the present invention was measured in 20 healthy women aged 30 to 45 years. First, women were divided into two groups (A and B), and the cosmetic composition according to the example was applied to the group A, and the cosmetic composition according to the comparative example was applied to the facial group twice a day (morning and evening) for 2 months. Before starting the experiment, measure the skin's brightness (L value) using the Chromameter (CR-300, Minolta) at the face area, and use the Chromameter at the same area of the face immediately after the experiment was finished. value) was measured. The increase rate of skin brightness by chromometer is the average value of skin L value after use of L value before use of the cream, and the measurement results are shown in Table 6 below.
As shown in the results of Table 6, the comparative example does not include a similar placental composition has almost no skin color improvement, when using an example containing a similar placental composition, it can be seen that the skin color improving effect is excellent.
Experimental Example 4: Moisturizing Improve clinical effect
The clinical effect of improving the moisturizing power of the cosmetic composition containing the similar placental composition of the present invention was measured in 20 healthy women aged 30 to 45 years. The women were selected as those with dry skin whose skin moisture was 65 or less. First, women were divided into two groups (A and B), and the cosmetic composition according to the embodiment was applied to the group A, and the cosmetic composition according to the comparative example was applied to the facial group twice a day (morning and evening) for 4 weeks. Before starting the experiment, the two parts to be measured were determined, the skin moisture content was measured three times, and then applied for 4 weeks (2 times / day), followed by a corneometer (Corneometer Courage) measuring device for skin moisture content. & Khazaka, Germany) to measure the moisture in the epidermal layer just below the stratum corneum. The measurement results are shown in Table 7.
As shown in the results of Table 7, when using an example containing a similar placental composition, it was confirmed that the water content increased more than two times after 28 days of application than when using a comparative example not included. This effect was observed in 75% of the subjects.
Claims (7)
100 parts by weight of the similar placental composition, 0.0000001 to 0.00001 parts by weight of fibroblast growth factor-2 (FGF-2), 0.000001 to 0.0001 parts by weight of Lantis (CCL5), 0.00000001 to 0.000001 parts by weight of interleukin-10 (IL-10) , Epithelial cell proliferation factor (EGF) 0.00001 to 0.001 parts by weight, transforming growth factor-β1 (TGFβ1) 0.0000001 to 0.00001 parts by weight, tumor necrosis factor-α (TNF-α) 0.00000001 to 0.000001 parts by weight, interleukin-8 (IL -8) Cosmetic composition for improving skin conditions comprising 0.000001 to 0.0001 parts by weight and 0.00000001 to 0.000001 parts by weight of interferon-γ (IFN-γ).
Similar placental compositions include activin, adiponectin, Ang, BMP, CSF, Flt-3 ligand, follistatin, fractalkin, GRO, HGF, hGH, I-309, IGF, IL-13, IL-15, IL-17, IL-1α IL-1β, IL-2, IL-3, IL-4, IL-6, IP-10, Raptin, MCP, MIP, PDGF-AA, PDGF-BB, Lecithin, sCD40L, SCF, SDF, Cosmetic composition for improving the skin condition further comprising one or more selected from the group consisting of TIMP and VEGF.
Skin condition improvement is a cosmetic composition for improving skin conditions, such as wrinkle improvement, regeneration, skin elasticity improvement, antioxidant, skin aging prevention, stretch marks improvement, slimming, wound healing, scar relief, mushroom improvement, whitening or moisturizing improvement.
Cosmetic composition for improving the skin condition comprising a similar placental composition, 0.000001 to 10 parts by weight based on the total weight of the cosmetic composition.
Fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ions A cosmetic composition for improving skin condition further comprising at least one selected from the group consisting of containment agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents and lipid vesicles.
Cosmetic composition includes skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, pack, soap, shampoo, cleansing foam A cleansing lotion, a cleansing cream, a body lotion, a body cleanser, an emulsion, a press powder, a loose powder, and an eye shadow.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110087685A KR20130024316A (en) | 2011-08-31 | 2011-08-31 | Cosmetic composition for improving skin condition comprising growth factor and cytokine induced human placenta |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110087685A KR20130024316A (en) | 2011-08-31 | 2011-08-31 | Cosmetic composition for improving skin condition comprising growth factor and cytokine induced human placenta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130024316A true KR20130024316A (en) | 2013-03-08 |
Family
ID=48176403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110087685A KR20130024316A (en) | 2011-08-31 | 2011-08-31 | Cosmetic composition for improving skin condition comprising growth factor and cytokine induced human placenta |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20130024316A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015037834A1 (en) * | 2013-09-10 | 2015-03-19 | 우리들휴브레인 주식회사 | Cosmetic composition containing peptide for skin regeneration |
| WO2015050316A1 (en) * | 2013-10-04 | 2015-04-09 | 박성율 | Skin enhancement method and system comprising six steps |
| KR20150070969A (en) * | 2013-12-16 | 2015-06-25 | 가톨릭대학교 산학협력단 | Composition for whitening containing proteins derived from mesenchymal stromal cells |
| CN111712227A (en) * | 2017-12-14 | 2020-09-25 | 绿十字生命健康有限公司 | Cosmetic and pharmaceutical compositions for relieving atopic dermatitis, alopecia and trauma or reducing skin wrinkles |
| WO2022255809A1 (en) * | 2021-06-02 | 2022-12-08 | 주식회사 엘지생활건강 | Placenta-mimic cosmectic composition |
-
2011
- 2011-08-31 KR KR1020110087685A patent/KR20130024316A/en not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015037834A1 (en) * | 2013-09-10 | 2015-03-19 | 우리들휴브레인 주식회사 | Cosmetic composition containing peptide for skin regeneration |
| WO2015050316A1 (en) * | 2013-10-04 | 2015-04-09 | 박성율 | Skin enhancement method and system comprising six steps |
| KR20150070969A (en) * | 2013-12-16 | 2015-06-25 | 가톨릭대학교 산학협력단 | Composition for whitening containing proteins derived from mesenchymal stromal cells |
| CN111712227A (en) * | 2017-12-14 | 2020-09-25 | 绿十字生命健康有限公司 | Cosmetic and pharmaceutical compositions for relieving atopic dermatitis, alopecia and trauma or reducing skin wrinkles |
| WO2022255809A1 (en) * | 2021-06-02 | 2022-12-08 | 주식회사 엘지생활건강 | Placenta-mimic cosmectic composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2492850C2 (en) | Fibroblast growth agent | |
| KR101809266B1 (en) | Cosmetic composition containing propolis complex extracts | |
| KR101480693B1 (en) | Anti-aging cosmetic composition for skin | |
| KR101382112B1 (en) | Composition of skin external application containing Chamaecyparis obtusa polysaccharide | |
| KR20160125784A (en) | Shiunko fermented oil and producing method thereof | |
| KR100849020B1 (en) | Cosmetic compositions comprising hydrolysis collagen peptide stabilized in nano-liposome | |
| KR20130024316A (en) | Cosmetic composition for improving skin condition comprising growth factor and cytokine induced human placenta | |
| KR101810226B1 (en) | Cosmetic compositon containing complex extracts from salmon | |
| KR20140060928A (en) | Skin external composition containing thioredoxin | |
| KR101512606B1 (en) | Cosmetic composition for improving wrinkle and atopic dermatitis and moisturizing | |
| CN113041172B (en) | Sebum membrane bionic composition for skin barrier repair, application thereof and cosmetics | |
| KR100843155B1 (en) | Cosmetic Compositions to stabilize Ascorbic acid | |
| KR20130068319A (en) | External composition for skin containing kalopanax pictus (thunb.) nakai extract | |
| KR20120017987A (en) | Cosmetic composition for removal the wrinkles at the corners of one's eyes | |
| KR101639578B1 (en) | Cosmetic composition containing Ocimum basilicum seed extract | |
| KR102303644B1 (en) | Face cosmetics fermentation composition comprising vegetable mixed extract and tumeric extract | |
| KR101208013B1 (en) | A skin-care agent containing mycoleptodonoides aitchisonii mycelium extract | |
| KR20160103983A (en) | Composition for reducing skin ageing disorders, comprising a retinaldehyde and a leontopodium alpinum extract | |
| KR20130046994A (en) | External composition for skin containing extract of potentilla stolonifera var. quelpaertensis nakai | |
| KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
| KR20130099610A (en) | Skin external composition containing sceptridium ternatum extract | |
| KR101884434B1 (en) | Skin external composition containing Pedicularis verticillata Linne var.hallaisanensis extract | |
| KR20100023372A (en) | Cosmetic composition containing phyllanthus urinaria extrancts | |
| KR20130008182A (en) | A cosmetic composition containing extract of camellia sasanqua | |
| KR20140081982A (en) | A skin-care agent containig Lyophyllum ulmarium fruit body extract or Lyophyllum ulmarium mycelium extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Withdrawal due to no request for examination |